Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Rectal Neoplasms × spartalizumab × Clear all

Phase

Phase 2 5 Phase 1 2 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Nasopharyngeal Carcinoma 4 Melanoma 2 Carcinoma, Hepatocellular 2 Uterine Cervical Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Skin Neoplasms 1 Recurrence 1 Rectal Neoplasms 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Locally Advanced Low Rectal Adenocarcinoma 1 HER2+ Breast Cancer 1 Epstein-Barr Virus Infections 1 Diabetes Mellitus, Insulin-Dependent, 12 1 Colorectal Neoplasms, Hereditary Nonpolyposis 1 Colorectal Neoplasms 1

Interventions

Fluorouracil 58 Leucovorin 53 Oxaliplatin 47 Capecitabine 36 Irinotecan 27 Bevacizumab 18 Radiotherapy 15 Folfox protocol 11 Chemoradiotherapy 11 Neoadjuvant Therapy 9 Chemotherapy, Adjuvant 9 Cetuximab 9 Drug Therapy 6 Surgical Procedures, Operative 5 XELOX 4 Panitumumab 4 Laparoscopy 4 FOLFOXIRI protocol 4 Transanal Endoscopic Microsurgery 3 Radiation 3 Octreotide 3 IFL protocol 3 Floxuridine 3 Diathermy 3 Trinitrotoluene 2 Tegafur 2 Semaxinib 2 Proctectomy 2 Occult Blood 2 Loperamide 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06507371 2025-06-26

mRCAT-III

Sir Run Run Shaw Hospital

Phase 3 Recruiting

Gastrointestinal

Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡